Claritas_updatedlogo.png
Claritas Announces Approval from OTC to Up-List to OTCQB
April 07, 2022 07:30 ET | Claritas Pharmaceuticals, Inc.
SAN FRANCISCO, CA and TORONTO, ON, April 07, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: CLAZF) (the "Company" or "Claritas") is pleased to announce...
Claritas_updatedlogo.png
Claritas Announces Approval from Australian Ethics Committee to Begin Phase 1 Trial of R-107
April 05, 2022 07:15 ET | Claritas Pharmaceuticals, Inc.
SAN FRANCISCO, CA and TORONTO, ON, April 05, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: CLAZF) (the "Company" or "Claritas") today announced that...
Claritas_updatedlogo.png
Claritas Announces Receipt of Comments from Australian Ethics Committee Regarding the Company’s Phase 1 Clinical Study of R-107 and Closing of Financing
February 22, 2022 07:30 ET | Claritas Pharmaceuticals, Inc.
SAN FRANCISCO, CA and TORONTO, ON , Feb. 22, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today announced that it has...
Claritas_updatedlogo.png
Claritas Anticipates Response from Australian Ethics Committee by February 18, 2022
February 09, 2022 07:15 ET | Claritas Pharmaceuticals, Inc.
SAN FRANCISCO, CA and TORONTO, ON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today announced that the...
Claritas_updatedlogo.png
Claritas Announces Revised, Improved Terms for Initial Tranche of Financing with Alumina Partners
January 26, 2022 17:50 ET | Claritas Pharmaceuticals, Inc.
SAN FRANCISCO, CA and TORONTO, ON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the “Company” or “Claritas”) today announced revised, improved...
Claritas_updatedlogo.png
Claritas Announces Letter of Intent to Acquire Worldwide Rights to R-107 for Treatment of Wound Healing, Skin Ulcers and Severe Burns
January 17, 2022 07:30 ET | Claritas Pharmaceuticals, Inc.
SAN FRANCISCO, CA and TORONTO, ON, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Claritas") today announced that it has signed...
Claritas_updatedlogo.png
Claritas Announces New Registered and Records Office Address, Confirms its Management and Directors and Announces Terms of Initial Tranche of Equity Financing with Alumina Partners
January 17, 2022 07:00 ET | Claritas Pharmaceuticals, Inc.
SAN FRANCISCO, CA and TORONTO, ON, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today announced the Company’s new...
Claritas_updatedlogo.png
Claritas Secures $5 Million Equity Financing Facility with Alumina Partners (Ontario) Ltd.
January 12, 2022 13:23 ET | Claritas Pharmaceuticals, Inc.
SAN FRANCISCO, CA and TORONTO, ON, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") is pleased to announce it has...
Claritas_updatedlogo.png
Claritas Outlines Development Strategy for R-107 for Multiple Diseases, Disorders and Injuries
January 04, 2022 07:30 ET | Claritas Pharmaceuticals, Inc.
SAN FRANCISCO, CA and TORONTO, ON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today outlined the Company’s...
Claritas_updatedlogo.png
Claritas to Develop R-107 for Treatment of PPHN, a Potentially Fatal Pulmonary Disorder in Newborns
December 22, 2021 07:15 ET | Claritas Pharmaceuticals, Inc.
SAN FRANCISCO, CA, and TORONTO, ON, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today announced that it will...